Jardiance Duo

Jardiance Duo Indications/Uses

empagliflozin + metformin

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH

Marketer:

Boehringer Ingelheim
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
Glycaemic control: JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions and Dosage & Administration).
Inadequately controlled with metformin or empagliflozin alone.
Inadequately controlled with empagliflozin or metformin in combination with other glucose- lowering products including insulin.
Already treated with empagliflozin and metformin co-administered as separate tablets.
Prevention of cardiovascular events: Empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
To prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in